reference/19383907

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/19383907

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	137
issn	0090-8258
issueIdentifier	1
pageRange	132-137
publicationName	Gynecologic Oncology
startingPage	132
bibliographicCitation	Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück HJ, Sehouli J, Gropp M, Stähle A, Schmalfeldt B, Meier W, Jackisch C; AGO Ovarian Cancer Study Group. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol. 2007 Apr;105(1):132–7. doi: 10.1016/j.ygyno.2006.10.053. PMID: 17161453.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47b509026bcb853f4745f34f6f5d3bf0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8eaed1a2933105814ddf6c3f4e53044 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83e81fe8a32a24371bf7ff18bcff8bca http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6250e5a96b3fbac542dc47151095cf52 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f37dfca348d94d9e8b56d88be0af3d71 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4486a6f41788e5d07bd4b1baf7c0c0c6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a75bf038b99bc6dbc5e09777a36a7409 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_99d96d51e058115b63956678c81f30a4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee523b8897f4fc48c43609fca62a93e9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_44b7a5b1e84040b506197cb22e6e5700 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_319cad0a9c48f48b5d386408727463a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ed93a982d15c6a53e1fd38f99a6e3617
date	200704
identifier	https://doi.org/10.1016/j.ygyno.2006.10.053 https://pubmed.ncbi.nlm.nih.gov/17161453
isPartOf	https://portal.issn.org/resource/ISSN/0090-8258 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3932
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆
discusses	http://id.nlm.nih.gov/mesh/M0443608 http://id.nlm.nih.gov/mesh/M0215357 http://id.nlm.nih.gov/mesh/M0444984 http://id.nlm.nih.gov/mesh/M0002922 http://id.nlm.nih.gov/mesh/M0021024 http://id.nlm.nih.gov/mesh/M0015422 http://id.nlm.nih.gov/mesh/M0018336
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D010051Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D009944Q000008 http://id.nlm.nih.gov/mesh/D000971Q000494 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D043823Q000008 http://id.nlm.nih.gov/mesh/D010349 http://id.nlm.nih.gov/mesh/D013629Q000008 http://id.nlm.nih.gov/mesh/D009944Q000494 http://id.nlm.nih.gov/mesh/D001952Q000008 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D011799Q000009 http://id.nlm.nih.gov/mesh/D011799Q000008 http://id.nlm.nih.gov/mesh/D001952Q000494 http://id.nlm.nih.gov/mesh/D004847Q000473 http://id.nlm.nih.gov/mesh/D000077156 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D013629Q000009 http://id.nlm.nih.gov/mesh/D043823Q000494 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D019008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7697 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9548828 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2733526 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123631 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6653 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6777 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23939

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135808554 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128713593 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129683629

Total number of triples: 75.